1. Home
  2. MTVA
  3. MTVA News

Latest METAVIA INC (MTVA) News on July 7, 2025

MTVA

Zacks Small Cap Research

9 days ago

OTC Markets Hosts Virtual Investor Presentation with HH Kim, President and CEO of MetaVia Inc., and David Bautz, PhD, Senior Analyst at Zacks SCR

MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…
MTVA

Zacks Small Cap Research

12 days ago

MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session
MTVA

PR Newswire

16 days ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Life Sciences Investor Forum: Now Available for Online Viewing
MTVA

GlobeNewswire

24 days ago

Life Sciences Investor Forum: Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for June 11th-12th
MTVA

GlobeNewswire

a month ago

Life Sciences Investor Forum Agenda Announced for June 11th-12th

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th
MTVA

GlobeNewswire

a month ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
MTVA

PR Newswire

a month ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…
MTVA

Zacks Small Cap Research

a month ago

MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
MTVA

GlobeNewswire

2 months ago

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
MTVA

PR Newswire

2 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
MTVA

PR Newswire

2 months ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
MTVA

PR Newswire

2 months ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
MTVA

PR Newswire

2 months ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
MTVA

PR Newswire

2 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…
MTVA

Zacks Small Cap Research

3 months ago

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…

MTVA

MT Newswires

3 months ago

MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability
MTVA

PR Newswire

3 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…
MTVA

Zacks Small Cap Research

3 months ago

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
MTVA

PR Newswire

4 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025
MTVA

Zacks Small Cap Research

6 months ago

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
MTVA

PR Newswire

6 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…
MTVA

Zacks Small Cap Research

7 months ago

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MTVA

PR Newswire

7 months ago

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MTVA

PR Newswire

7 months ago

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
MTVA

ACCESSWIRE

7 months ago

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
MTVA

GlobeNewswire

7 months ago

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…
MTVA

Zacks Small Cap Research

7 months ago

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

MetaVia to Present at the Emerging Growth Conference in December
MTVA

PR Newswire

7 months ago

MetaVia to Present at the Emerging Growth Conference in December

Share on Social Networks: